Joint AAPM/COMP Meeting , 2020

Preview:

Citation preview

FLASH RADIATION THERAPY – CURRENT STATUS AND THE WAY TO

THE CLINIC

LATEST RESULTS AND ADVANCES TOWARDS

CLINICAL FLASH-RT

Joint AAPM/COMP MeetingJuly 12th, 2020

Pierre Montay-Gruel, PhDUniversity of California Irvine

Latest results and advances towards clinical FLASH-RT

Latest preclinical results on the brain

Glioblastoma and cognition

Juvenile model toforesee medulloblastoma treatment

Clinical transfer

Which beam parameters ?

Which technology with electrons ?

What are the challenges ?

FLASH-RT is efficacious against GBM and protects the brain functions

Montay-Gruel et al (in revision)Please do not circulate

D+3 W1 W2 W3 W4

1

10

100

1000

10000

Time post tumor initiation (Weeks)

Rela

tive lum

inescence

(norm

aliz

ed to d

ay o

f R

T)

10 Gy

Control

10 Gy CONV

10 Gy FLASH

**

ns

0 5 10 15 20 25 30 35 40 45 50 55 60

0

25

50

75

100

Time post tumor initiation (days)

Perc

ent surv

ival

10 Gy

Control

10 Gy FLASH

10 Gy CONV

ns.

0

10

20

30

40

50

60

Dis

crim

inatio

n Index

10 Gy

Control 10 Gy CONV 10 Gy FLASH

***

D+3 W1 W2 W3 W41

10

100

1000

10000

Time post tumor initiation (Weeks)

Rela

tive lu

min

escence

(norm

aliz

ed to d

ay o

f R

T)

14 Gy

Control

14 Gy CONV

14 Gy FLASH

***

ns

0 5 10 15 20 25 30 35 40 45 50 55 60

0

25

50

75

100

Time post tumor initiation (days)

Perc

ent surv

iva

l

14 Gy

Control

14 Gy FLASH

14 Gy CONV

**

0

10

20

30

40

50

60

Dis

crim

ination Index

14 Gy

14 Gy CONV 14 Gy FLASHControl

**

ns

D+3 W1 W2 W3 W4

1

10

100

1000

10000

Time post tumor initiation (Weeks)

Rela

tive lu

min

escence

(norm

aliz

ed to d

ay o

f R

T)

2 x 7 Gy

Control

2 x 7 Gy CONV

2 x 7 Gy FLASH

ns

***

0 5 10 15 20 25 30 35 40 45 50 55

0

25

50

75

100

Time post tumor initiation (days)

Perc

ent surv

ival

2 x 7 Gy

Control

2 x 7 Gy FLASH

2 x 7 Gy CONV

ns.

0

10

20

30

40

50

60

Dis

crim

ination Index

2 x 7 Gy

2 x 7 Gy CONV 2 x 7 Gy FLASHControl

**

*

a. b. c.

d. e. f.

g. h. i.

Towards hypo-fractionation ?

Montay-Gruel et al (in revision)Please do not circulate

D+3 W1 W2 W3 W4

1

10

100

1000

10000

Time post tumor initiation (Weeks)

Rela

tive lu

min

escence

(norm

aliz

ed to d

ay o

f R

T)

4 x 3.5 Gy

Control

4 x 3.5 Gy CONV

4 x 3.5 Gy FLASH

ns

**

0 5 10 15 20 25 30 35 40 45 50 55 60 65

0

25

50

75

100

Time post tumor initiation (days)

Perc

ent surv

ival

4 x 3.5 Gy

Control

4 x 3.5 Gy FLASH

4 x 3.5 Gy CONV

ns.

0

10

20

30

40

50

60

Dis

crim

inatio

n Index

4 x 3.5 Gy

4 x 3.5 Gy CONV 4 x 3.5 Gy FLASHControl

ns

ns

D+3 W1 W2 W3 W4 W5 W6 W71

10

100

1000

10000

Time post tumor initiation (Weeks)

Rela

tive lu

min

escence

(norm

aliz

ed to d

ay o

f R

T)

3 x 10 Gy

Control

3 x 10 Gy CONV

3 x 10 Gy FLASH

****

ns

****

0 10 20 30 40 50 60 70 80 90 100

0

25

50

75

100

Time post tumor initiation (days)

Perc

ent surv

ival

3 x 10 Gy

3 x 10 Gy CONV

3 x 10 Gy FLASH

Control

*** ****

0

10

20

30

40

50

60

Dis

crim

inatio

n Index

3 x 10 Gy

3 x 10 Gy CONV 3 x 10 Gy FLASHControl

* *

a. b.

c. d.

e. f.

What about complete tumor control ?

Montay-Gruel et al (in revision)Please do not circulate

D+3 W1 W2 W3 W4 W5 W6 W71

10

100

1000

10000

Time post tumor initiation (Weeks)

Rela

tive lum

inescence

(norm

aliz

ed to d

ay o

f R

T)

25 Gy Hemibrain

Control

25 Gy CONV

25 Gy FLASH

****

ns

****

0 20 40 60 80 100 120 140 160 180 200 220 240

0

25

50

75

100

Time post tumor initiation (days)

Perc

ent surv

ival

25 Gy Hemibrain

25 Gy CONV

25 Gy FLASH

Control

****

0

10

20

30

40

50

60

Dis

crim

ination index

25 Gy Hemibrain

25 Gy CONV 25 Gy FLASHControl

nsns

a. b.

c.

Alaghband et al (Cancers, 2020)

Advantages of protecting the normal tissue

Medulloblastoma patients

→ Long term survival achieved >80% pediatric cases→ Surgery followed by cranio-spinal RT + chemo

→ Significant impairments cognition, mood disorders, endocrine dysfunction, cerebrovascular complications

WBRT 8 Gy FLASH / CONV-RT3 week old pups

Congnitive investigation

Memory

FearAnxiety

Social interactions

Conservation of complex congnitive functions in young animals

Alaghband et al (Cancers, 2020)

Absence of neurogenesis impairment Absence of neuroinflammation

Preservation of the endocrine system

Cellular preservation

Integrity of the adult cerebrovascular system after FLASH-RT

Preservation of tight junctions

Are electron beams suitable to transfer FLASH-RT to the clinics ?What are the challenges ?

Bourhis et al (Radiother&Oncol 2019)Montay-Gruel et al (in revision)

What do we know about the optimal parameters to obtain the FLASH effect ?

Wilson et al (Frontiers in Oncology, 2020)

What do we know about the optimal parameters to obtain the FLASH effect ?

Which technologies are currently available for a clinical transfer ?

What are the challenges ?

Wilson et al (Frontiers in Oncology, 2020)

External beam RT with 5-6 MeV LINAC is suitable for superficial skin tumor treatments

Intra Operative RT will overstep the depth penetration challenge associated with electron beams

Relatively high single dosesAccess to deeper tumorsExtremely fast beam-on time : advantage for surgeryProtection of the surrounding normal tissues

Multiple clinical applications

Conclusions

More and more preclinical data showing in different models

- Protection of the normal tissues: from cellular effect to organ function- Efficacious anti tumor effect with single doses or hypo fractionated regimen

Current studies are aiming at defining the optimal parameters to reach the FLASH effect

- Mean dose rate- Instantaneous (intra-pulse dose rate)- Pulse repetition (frequency)- Dose per pulse - Total dose- Total delivery time

Clinical tranfer is almost ready, with challenges yet to overcome (electrons)

- Penetration in the tissue (possibility of IORT or superficial tumors with EBRT)- No available VHEE technology available yet

MC Vozenin LabJ BourhisC YakkalaB PetitJ OllivierA De VallièreC GodfroidP Fuchs

F BochudC BailatJF GermondP FroideveauxN CherbuinT Buchillier

C Limoli LabJ BaulchM AcharyaV PariharY Alaghband

E GiedzinskyB AllenS Cheeks

Animal Facilities of Epalinges and Irvine

R MoeckliP Jorge-GoncalvesK PeterssonM JaccardM Gondre

Recommended